Replies to post #97802 on Biotech Values

[DewDiligence]

I wonder how this will affect ABT’s NGF mAb for pain. I’m referring to the recent deal where ABT paid an astounding $170M in up-front cash for a compound still in phase-1 (#msg-43510907).